Larkin J - Search Results

1

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R. Girotti MR, et al. Among authors: larkin j. Cancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14. Cancer Discov. 2013. PMID: 23242808 Free PMC article.

2

Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence.

Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME. Kolomainen DF, et al. Among authors: larkin jm. J Clin Oncol. 2002 Feb 15;20(4):982-6. doi: 10.1200/JCO.2002.20.4.982. J Clin Oncol. 2002. PMID: 11844820

3

The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress.

Larkin JM, Gore ME. Larkin JM, et al. Clin Oncol (R Coll Radiol). 2005 Aug;17(5):319-21. doi: 10.1016/j.clon.2005.03.007. Clin Oncol (R Coll Radiol). 2005. PMID: 16097560 No abstract available.

4

Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma.

Larkin JM, Norsworthy PJ, A'Hern RP, Eisen TG, Gore ME, Porter CD. Larkin JM, et al. Melanoma Res. 2006 Apr;16(2):157-63. doi: 10.1097/01.cmr.0000200490.62723.b0. Melanoma Res. 2006. PMID: 16567971

5

A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.

Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, Thomas K, Eisen TG, Gore ME. Larkin JM, et al. Br J Cancer. 2007 Jan 15;96(1):44-8. doi: 10.1038/sj.bjc.6603503. Epub 2006 Dec 5. Br J Cancer. 2007. PMID: 17146474 Free PMC article. Clinical Trial.

6

Drug insight: advances in renal cell carcinoma and the role of targeted therapies.

Larkin JM, Chowdhury S, Gore ME. Larkin JM, et al. Nat Clin Pract Oncol. 2007 Aug;4(8):470-9. doi: 10.1038/ncponc0901. Nat Clin Pract Oncol. 2007. PMID: 17657252 Review.

7

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.

Chowdhury S, Larkin JM, Gore ME. Chowdhury S, et al. Eur J Cancer. 2008 Oct;44(15):2152-61. doi: 10.1016/j.ejca.2008.06.028. Epub 2008 Sep 29. Eur J Cancer. 2008. PMID: 18829302 Review.

8

Malignant melanoma (metastatic).

Larkin J, Gore M. Larkin J, et al. BMJ Clin Evid. 2008 Aug 22;2008:1718. BMJ Clin Evid. 2008. PMID: 19445806 Free PMC article. Review.

9

Health policy: The UK 'postcode lottery' in renal cell carcinoma.

Larkin J, Gore M. Larkin J, et al. Nat Rev Urol. 2009 Dec;6(12):636-8. doi: 10.1038/nrurol.2009.228. Nat Rev Urol. 2009. PMID: 19956190 No abstract available.

10

The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells.

Rennalls LP, Seidl T, Larkin JM, Wellbrock C, Gore ME, Eisen T, Bruno L. Rennalls LP, et al. Immunology. 2010 Apr;129(4):610-9. doi: 10.1111/j.1365-2567.2009.03210.x. Epub 2010 Jan 13. Immunology. 2010. PMID: 20074207 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,274 results

Search Page

Filters